DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Satavaptan
Satavaptan
Article Efficacy and Tolerance of Urea Compared with Vaptans for Long
Hypernatremia: 2 Months Back When He Had Progressive Decrease in Vision (Right > Left)
Vaptans and the Treatment of Water-Retaining Disorders Friedericke Quittnat and Peter Gross
The Structure and Function of V1b Vasopressin Receptor
Management of Hyponatremia
Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study
Download Download
Vaptans and Hyponatremia in Critical Patients
Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide
The Treatment of Vasopressin V2-Receptor Antagonists in Cirrhosis Patients with Ascites
Assessment Report on the Withdrawal of the Marketing Application
Vasopressin Antagonists in the Treatment of Water-Retaining Disorders
Lixivaptan: a Vasopressin Receptor Antagonist for the Treatment of Hyponatremia
Table S1: Clinical Trials of AVP Antagonists and Agonists
When Is It Appropriate to Use Vasopressin Receptor Antagonists?
The Syndrome of Inappropriate Antidiuretic Hormone: Current And
View Eposter
Vasopressin Antagonists in Treatment of Hyponatremia
Top View
BMH Medical Journal 2015;2(4):106-109 Brief Review Vaptans
Vaptans Are Not the Mainstay of Treatment in Hyponatremia: Perhaps Not Yet Peter A
An Overview of Satavaptan: a Selective V2 Receptor Antagonist
WO 2016/100838 A2 23 June 2016 (23.06.2016) W P O P C T
When Is It Appropriate to Use Vasopressin Receptor Antagonists?
AVP Receptor Antagonists As Aquaretics: Review and Assessment of Clinical Data
Pharmaceutical Appendix to the Tariff Schedule 2